The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 16, 2021

Filed:

Jun. 02, 2017
Applicants:

University of South Florida, Tampa, FL (US);

University of Florida Research Foundation, Inc., Gainesville, FL (US);

Inventors:

Mildred Enid Acevedo-Duncan, Plant City, FL (US);

Wishrawana Ratnayake, Tampa, FL (US);

David A. Ostrov, Gainesville, FL (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/675 (2006.01); A61K 31/122 (2006.01); G01N 33/574 (2006.01); A61K 31/185 (2006.01); C12Q 1/6886 (2018.01); A61K 45/06 (2006.01); A61K 31/255 (2006.01); A61K 31/194 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/122 (2013.01); A61K 31/185 (2013.01); A61K 31/194 (2013.01); A61K 31/255 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); C12Y 207/11013 (2013.01); G01N 33/5743 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/91205 (2013.01); G01N 2800/52 (2013.01);
Abstract

The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-ζ and/or PKC-ι. Non-limiting examples of an inhibitor of PKC-ζ and/or PKC-ι include ICA-1 and ACPD. The invention also provides PKC-ζ and/or PKC-ι as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-ζ and/or PKC-ι. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-ζ and/or PKC-ι based on the levels and/or activity of PKC-ζ and/or PKC-ι mRNA or protein in the melanoma cells from the subject are also provided.


Find Patent Forward Citations

Loading…